384 related articles for article (PubMed ID: 29915896)
41. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation.
Kim JH; Nam B; Choi YJ; Kim SY; Lee JE; Sung KJ; Kim WS; Choi CM; Chang EJ; Koh JS; Song JS; Yoon S; Lee JC; Rho JK; Son J
Cancer Res; 2018 Aug; 78(16):4482-4496. PubMed ID: 29945964
[TBL] [Abstract][Full Text] [Related]
42. 30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).
de Marinis F; Ciardiello F; Baas P; Crinò L; Giaccone G; Grossi F; Hellmann MD; Mok TSK; Lena H; Paz-Ares L; Rodriguez-Abreu D; Von Pavel J; Gridelli C
ESMO Open; 2018; 3(4):e000298. PubMed ID: 29942662
[TBL] [Abstract][Full Text] [Related]
43. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
Niogret J; Coudert B; Boidot R
J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
[No Abstract] [Full Text] [Related]
44. Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
Wang Y; Liu Q; Chen H; You J; Peng B; Cao F; Zhang X; Chen Q; Uzan G; Xu L; Zhang D
Anticancer Drugs; 2018 Sep; 29(8):748-755. PubMed ID: 29927769
[TBL] [Abstract][Full Text] [Related]
45. Personalized therapy for lung cancer: striking a moving target.
Pakkala S; Ramalingam SS
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089719
[TBL] [Abstract][Full Text] [Related]
46. Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.
Gridelli C; Ascierto PA; Grossi F; Baldini E; Favaretto A; Garassino MC; Morabito A; Migliorino MR; Rossi A; de Marinis F
Curr Clin Pharmacol; 2018; 13(2):76-84. PubMed ID: 29992894
[TBL] [Abstract][Full Text] [Related]
47. Oncogene addicted non-small-cell lung cancer: current standard and hot topics.
Vecchiarelli S; Bennati C
Future Oncol; 2018 Jun; 14(13s):3-17. PubMed ID: 29989448
[TBL] [Abstract][Full Text] [Related]
48. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
[TBL] [Abstract][Full Text] [Related]
49. Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.
Murakami H; Nokihara H; Hayashi H; Seto T; Park K; Azuma K; Tsai CM; Yang JC; Nishio M; Kim SW; Kiura K; Inoue A; Takeda K; Kang JH; Nakagawa T; Takeda K; Akazawa R; Kaneko Y; Shimazaki M; Morita S; Fukuoka M; Nakagawa K
Cancer Sci; 2018 Sep; 109(9):2852-2862. PubMed ID: 29972716
[TBL] [Abstract][Full Text] [Related]
50. Adaptive Resistance to EGFR-Targeted Therapy by Calcium Signaling in NSCLC Cells.
Mulder C; Prust N; van Doorn S; Reinecke M; Kuster B; van Bergen En Henegouwen P; Lemeer S
Mol Cancer Res; 2018 Nov; 16(11):1773-1784. PubMed ID: 29967110
[TBL] [Abstract][Full Text] [Related]
51. Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Ashworth A; Lord CJ
Nat Rev Clin Oncol; 2018 Sep; 15(9):564-576. PubMed ID: 29955114
[TBL] [Abstract][Full Text] [Related]
52. GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.
Zeng L; Yang N; Zhang Y
J Thorac Oncol; 2018 Jul; 13(7):e114-e116. PubMed ID: 29935846
[No Abstract] [Full Text] [Related]
53. Can We Prevent Resistance to Osimertinib? Combination or Sequential.
Kim MH; Lim SM; Lee K; Soo RA; Cho BC
J Thorac Oncol; 2018 Jul; 13(7):877-879. PubMed ID: 29935843
[No Abstract] [Full Text] [Related]
54. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
[TBL] [Abstract][Full Text] [Related]
55. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.
Taniguchi Y; Horiuchi H; Morikawa T; Usui K
Case Rep Oncol; 2018; 11(2):323-329. PubMed ID: 29928211
[TBL] [Abstract][Full Text] [Related]
56. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in
Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV
Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210
[TBL] [Abstract][Full Text] [Related]
57. Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years.
Rybarczyk-Kasiuchnicz A; Ramlau R
Kardiochir Torakochirurgia Pol; 2018 Jun; 15(2):119-124. PubMed ID: 30069193
[TBL] [Abstract][Full Text] [Related]
58. Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.
Ohgami M; Kaburagi T; Kurosawa A; Doki K; Shiozawa T; Hizawa N; Homma M
Ther Drug Monit; 2018 Dec; 40(6):699-704. PubMed ID: 29995672
[TBL] [Abstract][Full Text] [Related]
59. Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review.
Ansari J; Batubara E; Ali M; Farrag A; Bashir F; Farghaly HR; Ali AM; Shaukat A
Mol Clin Oncol; 2018 Jul; 9(1):92-95. PubMed ID: 29977544
[TBL] [Abstract][Full Text] [Related]
60. Overcoming resistance in a
Schmid T; Buess M
Curr Oncol; 2018 Jun; 25(3):e217-e219. PubMed ID: 29962848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
